| Title |
Antidepressants for pain management in rheumatoid arthritis
|
|---|---|
| Published in |
Cochrane database of systematic reviews, November 2011
|
| DOI | 10.1002/14651858.cd008920.pub2 |
| Pubmed ID | |
| Authors |
Bethan L Richards, Samuel L Whittle, Rachelle Buchbinder |
| Abstract |
Pain management is a high priority for patients with rheumatoid arthritis (RA). Antidepressants are sometimes used as adjuvant agents to enhance pain relief, help with sleep and reduce depression. Such antidepressants include tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), selective serotonin noradrenaline reuptake inhibitors (SNRIs) and norepinephrine reuptake inhibitors (NRIs). However, the prescription of antidepressants in this population remains controversial because of conflicting scientific evidence. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Sweden | 2 | 50% |
| Unknown | 2 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 50% |
| Practitioners (doctors, other healthcare professionals) | 1 | 25% |
| Scientists | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 248 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | <1% |
| Spain | 1 | <1% |
| Sri Lanka | 1 | <1% |
| Brazil | 1 | <1% |
| Unknown | 244 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 49 | 20% |
| Student > Bachelor | 33 | 13% |
| Student > Ph. D. Student | 32 | 13% |
| Researcher | 21 | 8% |
| Student > Doctoral Student | 13 | 5% |
| Other | 28 | 11% |
| Unknown | 72 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 74 | 30% |
| Nursing and Health Professions | 29 | 12% |
| Psychology | 24 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 4% |
| Social Sciences | 8 | 3% |
| Other | 23 | 9% |
| Unknown | 80 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 June 2019.
All research outputs
#4,247,128
of 25,457,297 outputs
Outputs from Cochrane database of systematic reviews
#6,514
of 11,499 outputs
Outputs of similar age
#23,967
of 155,205 outputs
Outputs of similar age from Cochrane database of systematic reviews
#83
of 156 outputs
Altmetric has tracked 25,457,297 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,499 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 40.0. This one is in the 43rd percentile – i.e., 43% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 155,205 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 156 others from the same source and published within six weeks on either side of this one. This one is in the 46th percentile – i.e., 46% of its contemporaries scored the same or lower than it.